becton dickinson co septemb
becton dickinson co
bard boot perform
maintain buy rate upgrad tp
previous deriv tp base
non-gaap ep forward price-to-earnings multipl
provid upsid potenti
expect top-lin revenu growth
respect
estim base follow factor strong
revenu growth oper perform acquisit
bard tva medic strong growth segment revenu
strong product pipelin expect launch strong
growth develop emerg market
bd deliv strong perform quarter
strong growth revenu margin total revenu
increas due acquisit
 bard mid-singl digit growth across busi segment
net margin due achiev
oper effici continu improv
coupl posit impact cost synergi ep
non-gaap increas
compar
bd life scienc segment revenu increas
due strong perform across
preanalyt system diagnost system bioscienc
bd intervent segment revenu increas
due strong perform peripher
intervent urolog critic unit
compani namebecton dickinson companytickerbdxstock ratingbuyunchangedindustri viewoverweightpositivepric sep week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispidearavindra becton dickinson co septemb
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co septemb
bd medic segment revenu increas
due strong perform
medic deliveri solut medic
develop market revenu grew due
strong perform strength europ
surgeri md unit emerg market
revenu grew revenu china grew
due strong doubl digit growth life
scienc intervent segment revenu
latin america grew high singl digit
bd commerci releas bd abseq assay
analyz protein express single-cel level use
high-throughput sequenc bd also complet
acquisit tva medic inc sold advanc
bioprocess busi thermo fisher scientif
creat greater focu life scienc segment
bd expect total revenu grow adjust
ep growth expect
current price-to-earnings
due increas stock price quarter
price-to-earnings averag price-to-earnings
expect forward price-to-earnings
recommend buy rate stock tp
base bd perform
period acquisit bard expect top-lin
revenu grow base growth
develop emerg market perform across
segment
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date sep ex-dividend date sep last split factor new per last split date aug inform becton dickinson co septemb
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co septemb
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper profit interest incom special charges- interest incom incom incom net incom outstand dilut ep actual annual estim annual actual quarterli becton dickinson co septemb
 market account receivable- total prepaid current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr liabilities- minor interest total non-curr total prefer stock common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item becton dickinson co septemb
provid oper activ period increas compar
chang reflect gain sale remain interest vyair
medic ventur well discretionari cash contribut fund pension oblig
use invest activ period compar
capit expenditure-rel cash outflow net cash flow transfer acquisit
proce divestitur
provid financ activ period compar
june total world-wide cash short-term invest
depreciation- defer incom oper increas decreas increas decreas current assets- decreas increas payables- decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end becton dickinson co septemb
becton dickinson co deliv strong perform quarter
growth revenu due acquisit bard strong
total revenu increas compar
due acquisit bard currency-neutr basi revenu
increas prior-year period
total revenu increas compar
total intern revenu increas
compar
cog increas compar
gross profit increas compar
adjust gross profit increas
compar adjust gross margin
compar
compar
due
acquisit
increas
compar
sg expens increas compar
sg revenu compar
increas due higher sell gener
administr cost larg due inclus bard current-year
 expens increas compar
 expens revenu compar
increas due continu invest new
product platform well recognit certain write-down charg
bioscienc unit
acquisit restructur cost increas
compar oper margin increas
compar
becton dickinson co septemb
interest expens compar
interest expens rel flat compar prior-year period
unfavor impact higher level debt off-set
unfavor impact bridg financ commit fee incur
relat bard transact
gaap ep increas
compar
adjust effect tax rate compar
tax rate declin compar
due favor benefit specifi item current-year
total revenu
compar
net incom compar net loss
adjust net incom increas
compar
gaap ep increas compar non-
gaap ep increas compar
april divest remain interest vyair medic joint
ventur receiv gross cash proce recogn pre-
tax gain sale
record non-cash charg write
carri valu intang asset relat retir bd clic system
within bioscienc busi
total revenu period increas
compar cog period increas
compar
becton dickinson co septemb
sg expens period increas
compar sg expens revenu
period increas compar total revenu
increas due higher sell gener administr cost larg
due inclus bard current-year result
 expens period increas
compar expens revenu
period compar acquisit
restructur cost period compar
interest expens period increas
compar increas interest expens due
higher level debt due issuanc senior unsecur
 note
tax rate period compar
increas reflect less favor benefit specifi item
current-year period well certain effect new tax legisl
enact decemb
net incom period declin
compar ep period declin
compar
net incom
period declin
compar
total revenu
increas
compar
becton dickinson co septemb
total revenu increas compar
total revenu period increas
compar growth due
strong perform across bd medic bd life scienc
segment peripher intervent urolog critic unit
within bd intervent segment
total intern revenu increas
compar total revenu period increas
compar
revenu growth due strong perform across bd life scienc
segment medic deliveri solut medic manag
solut unit within bd medic segment surgeri peripher
intervent unit bd intervent segment
total revenu emerg market increas
compar previou year quarter total revenu
month period increas compar prior-
emerg market revenu current-year period also includ
estim favor impact due foreign currenc translat
revenu growth emerg market benefit inclus revenu
associ bard product financi result growth also due
sale china latin america
total revenu china increas
compar previou year quarter total revenu
period increas compar prior-year
total revenu develop market increas
compar previou year quarter total revenu
period increas compar prior-
total revenu
increas
compar
previou year
total revenu
china increas
compar
previou year
becton dickinson co septemb
bdx organiz structur base upon three princip busi segment
bd medic bd life scienc bd intervent
total revenu medic segment increas
compar total revenu
period segment increas compar
total revenu
increas
compar
medic segment growth favor impact inclus
revenu associ certain bard product within medic
deliveri solut unit revenu growth also due sale
medic deliveri solut unit vascular access vascular care
product well medic manag solut unit
instal dispens infus system
total revenu
solut increas
compar
total revenu increas compar
total intern revenu increas
compar
oper incom increas compar
oper margin increas
compar period oper margin
compar
total revenu medic deliveri solut increas
compar total revenu
period increas compar
total revenu increas
compar total intern revenu increas
compar
becton dickinson co septemb
total revenu
solut increas
compar
total revenu medic manag solut increas
compar total revenu
period increas compar
total revenu increas compar
total intern revenu increas
compar
total revenu diabet care increas
compar total revenu
period increas compar
total revenu increas compar
total intern revenu increas
compar
total revenu pharmaceut system increas
compar total revenu
month period increas compar
total revenu increas
compar total intern revenu increas
compar
total revenu
increas
compar
becton dickinson co septemb
total revenu life scienc segment increas
compar total revenu
period increas compar
total revenu increas compar
total intern revenu increas
compar
life scienc segment revenu growth due
growth three organiz unit growth
preanalyt system unit reflect global sale core product
diagnost system unit revenu due sale core
microbiolog product well continu strength sale unit bd
maxtm molecular platform growth also due bioscienc
unit sale research reagent advanc bioprocess product
oper profit increas compar
oper margin increas
compar oper margin period
compar
total revenu preanalyt system increas
compar total revenu
period increas compar
total revenu increas compar
total intern revenu increas
compar
total revenu life
increas
compar
total revenu
increas
compar
becton dickinson co septemb
total revenu diagnost system increas
compar total revenu
period increas compar
total revenu increas
compar total intern revenu increas
compar
total revenu bioscienc increas
compar total revenu period
increas compar
total revenu increas
compar total revenu period
increas compar
total revenu intervent segment increas
compar total revenu
period increas compar
total revenu increas compar
total intern revenu increas
compar
revenu includ reclassif certain product
revenu medic segment intervent segment
total revenu
increas
compar
total revenu
increas
compar
becton dickinson co septemb
oper profit increas compar
oper margin declin compar
oper margin period declin
compar
total revenu surgeri busi increas
compar total revenu period
increas compar
total revenu increas compar
total intern revenu increas
compar
total revenu peripher intervent increas
compar total revenu period
increas compar
total revenu increas compar
total intern revenu increas
compar
urolog critic
total revenu urolog critic busi
total revenu period
total revenu total intern
revenu
total revenu
increas
compar
total revenu
increas
compar
becton dickinson co septemb
integr integr carefus larg complet integr
bard proceed plan
synergi confid achiev carefus
bard expect realiz procur cost
save implement synergi project plan across busi function
revenu synergies- revenu synergi carefus good
traction intern portfolio md
grow high-singl digit sinc combin bd cfn
revenu synergi bard md vascular access salesforc cross-train
summer addit surgic salesforc train activ
synergi
confid achiev
carefus
bard
expect
save
busi function
becton dickinson co septemb
sodium chlorid
compound fy
bd venflon bd
bd abseq assay protein
bd instaflash
posit system
balloon length sfa
becton dickinson co septemb
bp
bp
total revenu
expect grow
adjust ep growth
expect
total revenu expect grow
adjust ep growth expect
effect tax rate
expect
effect tax rate expect
gross margin expect
oper incom expect grow
bd announc sale
advanc
thermo fisher
scientif creat
greater focu life
scienc segment
bd outstand
opportun
innov diseas
therapi research
clinic diagnost
becton dickinson co septemb
bd deliv strong perform quarter due acquisit
 bard mid-singl digit perform across medic life
scienc intervent segment revenu grew
net margin due achiev
oper effici continu improv coupl
posit impact cost synergi ep non-
gaap ep increas
bd life scienc segment world-wide revenu quarter
increas prior-year period growth reflect
strong perform across pre-analyt system diagnost system
bd medic segment world-wide revenu quarter
increas prior-year period growth due
strong perform medic deliveri solut medic
bd intervent segment world-wide revenu quarter
segment result reflect strong perform peripher
intervent urolog critic unit
bd announc commerci releas bd abseq assay analyz
protein express single-cel level use high-throughput sequenc
bd announc complet acquisit tva medic inc compani
develop minim invas vascular access solut patient
bd announc sale advanc bioprocess busi thermo
fisher scientif creat greater focu life scienc segment
bd outstand opportun contribut signific innov
diseas therapi research clinic diagnost
april bd divest remain interest vyair medic joint
ventur receiv gross cash proce recogn pre-tax
gain sale bd track integr bard
continu deliv financi commit provid innov
solut custom patient world-wide
becton dickinson co septemb
non- reconcili
non- reconcili
non- reconcili
oper tax oper tax becton dickinson co septemb
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co septemb
revenu growth ttm compar
ep growth declin ttm compar
oper margin declin ttm compar due increas sg
gross margin declin ttm compar due increas cog
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth becton dickinson co septemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale becton dickinson co septemb
inv flow sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale becton dickinson co septemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item becton dickinson co septemb
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale investment- issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free becton dickinson co septemb
current price-to-earnings due increas stock price
quarter price-to-earnings averag price-to-earnings
expect forward price-to-earnings
bandp/eaverageavg stdevavg stdev becton dickinson co septemb
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co septemb
breakdown share held share held float held institut hold institut holdersholdershar report outvaluepric row associ vanguard group inc fmr fundsmith jp morgan well fargo putnam invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row growth stock fund spdr etf price row chip growth fund price row capit appreci franklin manag trust rise dividend vanguard institut fund-institut fidel select portfolio medic technolog devic price row becton dickinson co septemb
compani name/symbolcurr yr epsgrowthbecton dickinson minor becton dickinson co septemb
developmentsbd statement divestitur advanc bioprocess businessseptemb announc sale advanc bioprocess busi sale advanc bioprocess busi creat greater focu life scienc segment bd outstand opportun contribut signific innov diseas therapi research clinic diagnost bd award million grant help commun health center drive effect medic use among vulner patientsaugust relief thenat associ commun health center nachc recent award five commun health center total millionin grant fund use expand program help vulner patient effect manag medic fund part bd help build commun program initi fund bd implement togeth direct relief nachc provid award elig commun health center support innov approach health care underserv vulner popul bd drive futur immunolog research expand offer simultan rna protein express analysisjuli announc commerci releas thebdabseq assayto analyz protein express single-cel level use high-throughput sequenc assay bring togeth high-qual antibodi bd pharmingen portfolio oligonucleotid allow research perform single-cel protein analysi bd rhapsodi single-cel analysi system use togeth research tool enabl research simultan analyz rna protein thousand individu cell develop complet pictur role gene protein play biolog system bd acquir tva medic advanc leadership solut chronic kidney diseasejuli announc complet acquisit oftva medic inc compani develop minim invas vascular access solut patient chronic kidney diseas requir hemodialysi addit tva medic enabl bd offer everlinq endoavf system new endovascular arterioven av fistula creation technolog add compani esrd portfolio dialysi cathet drug coat balloon standard angioplasti balloon endovascular stent graft product technolog improv bd abil serv physician patient provid minim invas option creat critic av fistula hemodialysi procedur becton dickinson co septemb
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co septemb
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit becton dickinson co septemb
consensu view analyst trend stock
forecast
compar
 average
multipl
compar
valuat comparisonbdxindustri avg avgprice/earn yield avgfive-year growth forecast usdgrowth high day day day estim becton dickinson co septemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr becton dickinson co septemb
price target summarycrispidea morgan capitalinitaitedmarket isi fargoinitiatedoutperformrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext becton dickinson co septemb
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co septemb
stock price show upward trend period surg
return stock averag volum share trade
 price movementvolumeclos becton dickinson co septemb
stock volatil till may later show upward trend due develop
pipelin compani
stock gave return past one-year rang stock
 price movementvolumeclos becton dickinson co septemb
stock price show upward trend past three year due strong growth busi
stock given return past
 year price movementvolumeclos becton dickinson co septemb
deliv strong perform quarter growth revenu
growth due acquisit bard strong growth across busi segment
recommend buy rate stock tp
closeci target becton dickinson co septemb
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
